| Erin E Cook, AA | |
|
33300 Cleveland Clinic Blvd, Avon, OH 44011-1172 | |
| (440) 695-5000 | |
| Not Available |
| Full Name | Erin E Cook |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 14 Years |
| Location | 33300 Cleveland Clinic Blvd, Avon, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639497860 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 67.000330 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic Avon Hospital | Avon, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
A clinical trial exploring a new minimally invasive treatment option for some patients with severe aortic stenosis recently launched at Baylor Jack and Jane Hamilton Heart and Vascular Hospital.
Every third teenager has suffered from one mental disorder and one physical disease. These co-occurrences come in specific associations: More often than average, depression occurs together with diseases of the digestive system, eating disorders with seizures and anxiety disorders together with arthritis, heart disease as well as diseases of the digestives system.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
Reuters and The Wall Street Journal challenge the notion, based on recent jobs data, that the health law is causing an erosion of full-time work. Other media outlets look at the endangered status of new insurance co-ops funded by the law, the high price of many prescription drugs and concerns about the people enrolled in high-risk insurance pools that will close at the end of the year.
› Verified 5 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
A clinical trial exploring a new minimally invasive treatment option for some patients with severe aortic stenosis recently launched at Baylor Jack and Jane Hamilton Heart and Vascular Hospital.
Every third teenager has suffered from one mental disorder and one physical disease. These co-occurrences come in specific associations: More often than average, depression occurs together with diseases of the digestive system, eating disorders with seizures and anxiety disorders together with arthritis, heart disease as well as diseases of the digestives system.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
Reuters and The Wall Street Journal challenge the notion, based on recent jobs data, that the health law is causing an erosion of full-time work. Other media outlets look at the endangered status of new insurance co-ops funded by the law, the high price of many prescription drugs and concerns about the people enrolled in high-risk insurance pools that will close at the end of the year.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin E Cook, AA 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: (216) 444-2200 | Erin E Cook, AA 33300 Cleveland Clinic Blvd, Avon, OH 44011-1172 Ph: (440) 695-5000 |
News Archive
A clinical trial exploring a new minimally invasive treatment option for some patients with severe aortic stenosis recently launched at Baylor Jack and Jane Hamilton Heart and Vascular Hospital.
Every third teenager has suffered from one mental disorder and one physical disease. These co-occurrences come in specific associations: More often than average, depression occurs together with diseases of the digestive system, eating disorders with seizures and anxiety disorders together with arthritis, heart disease as well as diseases of the digestives system.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
Reuters and The Wall Street Journal challenge the notion, based on recent jobs data, that the health law is causing an erosion of full-time work. Other media outlets look at the endangered status of new insurance co-ops funded by the law, the high price of many prescription drugs and concerns about the people enrolled in high-risk insurance pools that will close at the end of the year.
› Verified 5 days ago
Bianca M. Shah, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2400 N Star Ln, Avon, OH 44011 Phone: 440-623-2340 |